<DOC>
	<DOCNO>NCT00681876</DOCNO>
	<brief_summary>This phase II study evaluate efficacy combination two monoclonal antibody ( Avastin + Erbitux ) irinotecan , patient colorectal cancer progress 1st line treatment FOLFIRI Avastin XELIRI Avastin .</brief_summary>
	<brief_title>Phase II Study Avastin + Erbitux + Irinotecan 2nd Line Treatment Colorectal Cancer</brief_title>
	<detailed_description>Treating patient primary resistance active multi-agent combination remain challenge clinical problem . The report data demonstrate addition ERBITUX may reverse IRINOTECAN resistance . Further data support feasibility combination two monoclonal antibody ( AVASTIN+ERBITUX ) IRINOTECAN good response compare historical control ( ERBITUX±IRINOTECAN ) . As , phase II study design evaluate efficacy combination AVASTIN plus ERBITUX plus IRINOTECAN second line treatment patient progress treatment FOLFIRI AVASTIN XELIRI AVASTIN</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm locally advanced metastatic colorectal cancer . Measurable evaluable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) ECOG performance status ≤ 2 Age 18 72 year Patients de novo refractory disease ( progression disease best response 1st line therapy FOLFOX/Avastin ) Adequate liver ( Bilirubin ≤ 1.5 UNL , SGOT/SGPT ≤ 4 UNL , ALP ≤ 2.5 UNL ) , renal ( Creatinine ≤ 1.5 UNL ) bone marrow ( ANC ≥ 1,500/mm3 , PLT ≥100,000/mm3 ) function Patients must able understand nature study Written inform consent History serious cardiac disease ( unstable angina , congestive heart failure , uncontrolled cardiac arrhythmia ) . History myocardial infarction stroke within 6 month . Clinically significant peripheral vascular disease . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day prior Day 0 . Presence central nervous system brain mets . Evidence bleed diathesis coagulopathy . Patients know hypersensitive reaction cetuximab Blood pressure &gt; 150/100 mmHg . Pregnant lactate woman . Life expectancy &lt; 3 month . Previous radiotherapy within last 4 week &gt; 25 % bone marrow . Metastatic infiltration liver &gt; 50 % . Patients chronic diarrhea ( least 3 month ) partial bowel obstruction total colectomy . Active infection require antibiotic Day 1 . Second primary malignancy , except nonmelanoma skin cancer situ cervical cancer . Psychiatric illness social situation would preclude study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Second line</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Erbitux ( Cetuximab )</keyword>
	<keyword>Avastin ( Bevacizumab )</keyword>
</DOC>